← FDA DRUG APPROVALS

FDA ANDA · ANDA077743

RIBAVIRIN

Sponsor: SANDOZ

APPLICATION
ANDA077743
TYPE
ANDA
ORIGINAL APPROVAL
2006-10-03
LATEST ACTION
2016-01-09
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

RIBAVIRINPrescription
RIBAVIRIN 200MG · TABLET · ORAL

Approval history

2016-01-09Labeling · Supplement 9 · standardAP
2016-01-09Labeling · Supplement 7 · standardAP
2011-11-30Labeling · Supplement 6AP
2008-08-27Labeling · Supplement 4AP
2008-03-20Manufacturing (CMC) · Supplement 1AP
2008-03-05Labeling · Supplement 3AP
2006-10-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →